SCHEMBL3066546

SCHEMBL3066546

CC(C)(C)S(=O)(=O)Nc1ccccc1[C]=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.43
CA2 P00918 4/20 0.40
CA1 P00915 3/20 0.36
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
SLC40A1 Q9NP59 1/20 0.35
UQCRB P14927 1/20 0.33
HSD17B2 P37059 1/20 0.33
SLC16A3 O15427 1/20 0.33
PSIP1 O75475 1/20 0.33
HTR6 P50406 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KEAP1 Q14145 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3031664 0.79 KEAP1 (0.52) ALDH1A1HTTL3MBTL1KEAP1PTGS1
SCHEMBL10444464 0.76 PSIP1 (0.58) SLC22A12HTTPSIP1PTGS1PTGS2
SCHEMBL11787881 0.76 SLC16A3 (0.38) SLC22A12CA2CA1HTTSLC16A3
SCHEMBL12932924 0.76 ALDH1A1 (0.50) CA2ALDH1A1KEAP1PTGS1PTGS2
SCHEMBL14830771 0.74 PSIP1 (0.59) SLC22A12CA2CA1ALDH1A1PDK1
SCHEMBL5849242 0.74 CA2 (0.46) CA2CA1HTTPDK1PDK2
SCHEMBL3059170 0.72 PARP14 (0.46) SLC22A12ALDH1A1PSIP1PTGS1
SCHEMBL20290538 0.71 KMT2A (0.55) SLC22A12CA2CA1ALDH1A1SLC40A1
SCHEMBL3831681 0.71 CA2 (0.40) CA2CA1UQCRBHSD17B2
SCHEMBL3066548 0.71 CYP2C9 (0.55) CA2CA1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 SLC22A12 2726/4885CA2 1345/4885CA1 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.